UK Markets closed

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
5.45-0.09 (-1.62%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close5.54
Open5.64
Bid5.37 x 1400
Ask5.80 x 1400
Day's range5.35 - 5.65
52-week range4.75 - 25.04
Volume315,198
Avg. volume911,509
Market cap104.633M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date12 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.00
  • Globe Newswire

    Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today the closing of its follow-on public offering of 3,942,856 American Depositary Shares ("ADSs"), at a public offering price of $7.00 per ADS, which includes the exercise in full o

  • Globe Newswire

    Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update

    Expect to close our follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) for gross proceeds of $27.6 million before deducting underwriter fees and commissions and other offering expensesData reported in early July 2021 from EVX-01 Phase 1/2a clinical trial showed a robust anti-tumor effect in combination with anti-PD-1 treatment for patients with metastatic melanoma, supporting advancement into a Phase 2b clinical trialData also reported i

  • Globe Newswire

    Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering

    COPENHAGEN, Denmark, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today the pricing of its follow-on public offering of 3,428,571 American Depositary Shares ("ADSs"), at a public offering price of $7.00 per ADS, with each such ADS representing one o